Targeting of ibrutinib resistance–driving pathways by miR-28 in ABC-DLBCL
Open Access
- 8 April 2026
- journal article
- Published by Springer Nature in Leukemia
- Vol. 40 (5) , 894-905
Abstract
Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive B-cell lymphoma. Although many patients respond well to R-CHOP immunochemotherapy, those with the activated B-cell (ABC) subtype are often refractory or relapse. Bruton tyrosine kinase (BTK) inhibitors such as ibrutinib have improved outcomes, but acquired resistance limits their long-term efficacy. Here, we modeled the development of ibrutinib resistance in ABC-DLBCL and investigated whether the BCR-signaling regulator microRNA-28 (miR-28) can block this process. Using flow cytometry-based competition assays, multicolor clonal barcoding, transcriptomic profiling, and xenograft models, we found that miR-28 expression impairs the emergence of ibrutinib-resistant ABC-DLBCL cells. Mechanistically, miR-28 interferes with the clonal selection process triggered by ibrutinib treatment and rewires transcriptional programs by downregulating mitochondrial and mTOR signaling pathways critical for resistance development. Furthermore, the miR-28-repressed gene signature associated with ibrutinib resistance correlates with improved survival in ibrutinib-treated patients from the PHOENIX trial cohort with the MCD genetic subtype, which is associated with ABC-DLBCL. Finally, the targeted therapeutic delivery of miR-28 via aptamer-guided nanoparticles suppresses ibrutinib-resistant tumor growth in vivo. These findings identify miR-28 as an effective inhibitor of ibrutinib resistance, underscoring its translational potential as an adjunct strategy in ABC-DLBCL therapy.Keywords
All Related Versions
This publication has 42 references indexed in Scilit:
- BTK inhibitors resistance in B cell malignancies: Mechanisms and potential therapeutic strategiesBlood Reviews, 2025
- Response to Bruton’s tyrosine kinase inhibitors in aggressive lymphomas linked to chronic selective autophagyCancer Cell, 2024
- Clinical translation of gold nanoparticlesDrug Delivery and Translational Research, 2022
- Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCLCancer Cell, 2021
- 2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and managementAmerican Journal of Hematology, 2021
- miRNA-Based Therapies in B Cell Non-Hodgkin LymphomaTrends in Immunology, 2020
- Genetic and Functional Drivers of Diffuse Large B Cell LymphomaCell, 2017
- PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatmentLeukemia, 2017
- Roles for MicroRNAs in Conferring Robustness to Biological ProcessesCell, 2012
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profilingNature, 2000